ArticleNature medicine2021
Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.
Abstract readPublished Erratum
In one paragraph
Article in Nature medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- CD8Cell reports. Medicine · 2026Review
- CRISPR-screen informed engineered T cell therapies.Frontiers in immunology · 2026Review
- Mechanistic basis and therapeutic modulation of T cell fitness to enhance CAR-T cell efficacy in hematological malignancies.Frontiers in immunology · 2026Review
- Supercharging the metabolic engine: mitochondrial engineering strategies for CAR-T persistence in solid tumors.Frontiers in immunology · 2026Review
- Current status of chimeric antigen receptor T cell therapy and its exhaustion mechanism.Immunotherapy · 2025Review
- Richter Transformation in Chronic Lymphocytic Leukemia: Current Treatment Challenges and Evolving Therapies.International journal of molecular sciences · 2025Review
- Age-associated nicotinamide adenine dinucleotide decline drives CAR-T cell failure.Nature cancer · 2025Article
- Secretion of a VEGF-Blocking scFv Enhances CAR T-cell Potency.Cancer immunology research · 2025Article
- Mechanisms of antigen-dependent resistance to chimeric antigen receptor (CAR)-T cell therapies.Cancer cell international · 2025Review
- Research progress on tumor-infiltrating lymphocyte therapy for cervical cancer.Frontiers in immunology · 2025Review
- The Emerging Role of Induced Pluripotent Stem Cells as Adoptive Cellular Immunotherapeutics.Biology · 2023Review
- Light-inducible T cell engagers trigger, tune, and shape the activation of primary T cells.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- AKT inhibition generates potent polyfunctional clinical grade AUTO1 CAR T-cells, enhancing function and survival.Journal for immunotherapy of cancer · 2023Article
- Role of CAR T Cell Metabolism for Therapeutic Efficacy.Cancers · 2022Review
- Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2-specific T cell therapy products.Molecular therapy. Methods & clinical development · 2022Article
Corrections and comments
- Erratum for
Authors and funding
37 authors.
Joseph A FraiettaDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Simon F Lacey *Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Elena J Orlando *Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
Iulian Pruteanu-MaliniciNovartis Institutes for BioMedical Research, Cambridge, MA, USA.
Mercy GohilCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Stefan LundhCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Alina C BoesteanuCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Yan WangCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Roddy S O'ConnorCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Wei-Ting HwangDepartment of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA.
Edward PequignotCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
David E AmbroseCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Changfeng ZhangCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Nicholas WilcoxCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Felipe BedoyaCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Corin DorfmeierCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Fang ChenCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Lifeng TianCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Harit ParakandiCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Minnal GuptaCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Regina M YoungCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
F Brad JohnsonDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-7443-7227
Irina KulikovskayaCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Li LiuCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Jun XuCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-6969-0693
Sadik H KassimNovartis Institutes for BioMedical Research, Cambridge, MA, USA.
Megan M DavisDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Bruce L LevineDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-6971-8465
Noelle V FreyCenter for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
Donald L SiegelDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Alexander C HuangParker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, USA.
E John WherryParker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, USA.
Hans BitterNovartis Institutes for BioMedical Research, Cambridge, MA, USA.
Jennifer L BrogdonNovartis Institutes for BioMedical Research, Cambridge, MA, USA.
David L PorterDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Carl H JuneDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-0241-3557
J Joseph MelenhorstDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA. mej@upenn.edu.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
PMID
33547459What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.